Gary Sweeney

PhD (University of Glasgow)
Professor
E–mail: gsweeney@yorku.ca
Research Areas: Medical Pharmacology, Cell Biology, Biotechnology

Research in Sweeney Lab:

Obesity is a major risk factor for development of diabetes and heart failure. The former initially involves development of insulin resistance, when the body does not respond well to the hormone insulin. The latter occurs when the heart is unable to pump sufficient blood to meet the demands of the body. Progression of heart failure is now commonly believed to result due to a complex interplay of detrimental effects (remodeling). The ability of adipokines (substances released by adipose tissue, such as adiponectin) to mediate the connection between obesity and diabetes or heart failure is a major focus of our lab. Research in our lab is funded by CIHR, NSERC, Heart & Stroke Foundation and Thalassemia Foundation.

Our collaborative network includes research groups across Canada as well as in Hong Kong, Thailand, South Korea and United Kingdom. Our work may aid the development of therapeutic strategies for the treatment of cardiometabolic diseases in obesity. Indeed, we have close partnership with a pharmaceutical company to aid in the development of adiponectin-based therapeutics.

Instagram: https://www.instagram.com/sweeneylab/ 
Facebook: https://www.facebook.com/sweeneylab/
Webpage: https://garysweeneyblog.wordpress.com/

Information for Prospective Graduate Students

Our lab expects to accept both PhD. and MSc. students for entry in Fall 2020. In doing so we look for potential graduate students who have related research experience and demonstrated skills, a strong academic record, are creative and highly motivated, and whose interests match on-going work in the lab.
Prospective students may provide a statement of your interests, a CV and (unofficial) transcript. Letters of recommendation will be requested prior to acceptance for graduate school

Representative  Publications:

Song E, Da Eira D, Jani S, Sepa-Kishi D, Vu V, Hunter H, Lai M, Wheeler MB, Ceddia RB & Sweeney G.

Cardiac autophagy deficiency attenuates ANP production and disrupts myocardial-adipose crosstalk leading to increased fat accumulation and metabolic dysfunction

Diabetes (2020: in press)

Huang X, Slavkovic S, Song E, Botta A, Mehrazma B, Lento C, Johnson PE, Sweeney G, Wilson DJ.

A Unique Conformational Distortion Mechanism Drives Lipocalin 2 Binding to Bacterial Siderophores.

ACS Chemical Biology. (2020) 15(1):234-242

Byrne NJ, Matsumura N, Alma'ayah Z, Ferdaoussi M, Takahara S, Essa AD, Levasseur JL, Jahng JWS, Vos D, Parajuli N, Braam B, Young ME, Verma S, Sweeney G, Seubert JM and Dyck JRB

Empagliflozin Improves Cardiac Function in Heart Failure by Suppressing Activation of the NLRP3 Inflammasome

Circulation Heart Failure (2020) 13(1):e006277

Jahng JWS, Alsaadi RM, Rengasamy P, Song E, Hipolito VEB, Sung HK, Botelho RJ, Russell, RC & Sweeney G.

Iron overload inhibits late stage autophagy flux leading to insulin resistance

EMBO Reports (2019) 20(10):e47911

Yoon, N , Dadson, K. Sung, KH. Chu, T. Kim, S. Jeon, JS. Grant, J. McKee, T. Peterson, J, Kelly, SP. & Sweeney G.

Tracking adiponectin biodistribution via fluorescence molecular tomography indicates increased vascular permeability after streptozotocin-induced diabetes

American Journal of Physiology (2019) 317(5):E760-E772

Song E, Ramos SV, Huang X, Liu Y, Botta A, Sung HK, Turnbull PC, Wheeler MB, Berger T, Wilson DJ, Perry CGR, Mak TW, Sweeney G.

Holo-lipocalin-2-derived siderophores increase mitochondrial ROS and impair oxidative phosphorylation in rat cardiomyocytes

Proc Natl Acad Sci U S A. 2018 115(7):1576-1581